Across TCGA pan-cancer cohorts, RNU6-1169P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RNU6-1169P’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where RNU6-1169P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-1169P is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

PRAD and KIRC are the cancer types where RNU6-1169P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1169P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.140	.013	2	view →
KIRC	All	All	−0.033	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RNU6-1169P RNA expression & survival · all RNU6-1169P data types